Dengue vaccine candidates in development

Anna P. Durbin, Stephen S. Whitehead

Research output: Chapter in Book/Report/Conference proceedingChapter

75 Scopus citations


Each of the DENV serotypes can cause the full spectrum of dengue illness. Epidemiological studies have implicated preexisting heterotypic DENV antibody as a risk factor for more severe disease upon secondary DENV infection. For these reasons, a successful DENV vaccine must protect against all four DENV serotypes. Live attenuated DENV vaccine candidates are the furthest along in development and clinical evaluation. Two live attenuated tetravalent vaccine candidates are in Phase 2 clinical trials in DENV endemic regions. Numerous other vaccine candidates including inactivated whole virus, recombinant subunit protein, DNA and virus-vectored vaccines are also under development. Those DENV vaccine candidates that have been evaluated in preclinical animal models or in clinical trials will be discussed.

Original languageEnglish (US)
Title of host publicationDengue Virus
EditorsAlan Rothman
Number of pages15
StatePublished - 2009
Externally publishedYes

Publication series

NameCurrent Topics in Microbiology and Immunology
ISSN (Print)0070-217X

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology
  • Immunology
  • Microbiology (medical)


Dive into the research topics of 'Dengue vaccine candidates in development'. Together they form a unique fingerprint.

Cite this